Related Content
Jan. 27, 2026 — Cytokinetics, Inc. has announced that Myqorzo (aficamten) is now available for prescription in 5 mg, 10 ...
January 28, 2026
Sept. 30, 2024 — Cytokinetics, Inc. recently announced that additional analyses synthesizing data from SEQUOIA-HCM ...
October 02, 2024
May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...
May 14, 2024April 13, 2007 — Cytokinetics Inc. announced yesterday the initiation of Phase II clinical trials program evaluating CK ...
April 11, 2007